Spectrum Pharmaceuticals Strengthens Commercial Operations

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the promotions of Rick Gonzalez to Senior Vice President, Commercial; Andrew W. Amstrup to the position of Vice President, Sales, and Glenn Ravelo to Vice President, Business Solutions. “The promotions of Rick, Andy and Glenn on our Commercial team will further strengthen our position and results in the marketplace,” said Jim Shields, Spectrum Pharmaceuticals’ Senior Vice President and Chief Commercial Officer. “Each of these individuals has contributed significantly to our success and our ability to capitalize on current and future market opportunities in oncology and hematology.”

“The promotions are intended to reward our commercial team for its successes in 2011 and are also crucial as we ramp up our commercial efforts for the future,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We expect to continue to grow sales for our two marketed drugs, FUSILEV® for advanced metastatic colorectal cancer, and ZEVALIN® for indolent non-Hodgkin’s lymphoma. We currently expect our fourth quarter 2011 revenues to be equal to or greater than our third quarter 2011 revenues.”

Rick Gonzalez joined Spectrum in March 2008 and has had increasing responsibilities leading teams within Spectrum’s Commercial group. In his new position of Senior Vice President, Commercial, Mr. Gonzalez will be responsible for designing and leading all commercial strategies for marketed and late-stage products, including Sales, Commercial Operations, Business Solutions and Brand Management. His immediate focus is on the optimization of all resources within the commercial operation to ensure a successful launch of the ZEVALIN (ibritumomab tiuxetan)repositioning campaign and continued revenue growth from FUSILEV (levoleucovorin). Mr. Gonzalez will report directly to Jim Shields. Prior to joining Spectrum, Mr. Gonzalez was a founding member of the Abraxis Oncology commercial team, where he held positions in sales management, marketing and account management. Mr. Gonzalez has 20 years of experience in the pharmaceutical industry of which 14 have been in specialty markets, including Hematology/Oncology. Prior companies include GlaxoSmithKline, Roche Laboratories, Ligand Pharmaceuticals and Genzyme. Mr. Gonzalez earned his Bachelor of Science in Business Logistics from Penn State University.

Andrew Amstrup joined Spectrum in 2011, serving most recently as National Director of Sales for ZEVALIN. In his new position of Vice President, Sales, Mr. Amstrup will report to Mr. Gonzalez and will be responsible for the Company’s Academic and Specialty Hematology ZEVALIN sales teams. Mr. Amstrup has more than 30 years of pharmaceutical sales and sales management experience. Prior to joining Spectrum, he was Director of Sales for TEVA Pharmaceuticals, where he managed seven sales districts including 72 field representatives and managers. Mr. Amstrup previously spent 20 years with Bayer Corporation, most recently as Specialty Director of Sales in the Academic and Institutional Environment. Early in his career, he was Division Manager with Stuart Pharmaceuticals (now AstraZeneca PLC). Mr. Amstrup earned his Bachelor of Arts from California State University.

Glenn Ravelo has more than 25 years of pharmaceutical experience, including 21 in the oncology space. Mr. Ravelo is a seasoned professional with extensive experience in sales, sales management and account management. In his new role as Vice President of Business Solutions, Mr. Ravelo will be responsible overseeing the FUSILEV Specialty Sales Team. In addition, his responsibilities will include: Account Management, Managed Markets, Government Affairs, Logistics and Business Informatics. He will report to Mr. Gonzalez. Prior to joining Spectrum in 2007, he held various positions of increasing responsibility at Abraxis Oncology. Mr. Ravelo was a charter member of Amgen Corporation where he spent 18 years and gained experience in many areas of the business. Previously, he worked at Roche Laboratories. Mr. Ravelo earned his Bachelor of Science from Springhill College and his Master of Business Administration from Nova Southeastern.